POLYNOVO LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.965 AUD | -4.61% |
|
-8.60% | +18.73% |
| Mar. 04 | Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace | MT |
| Feb. 27 | Transcript : PolyNovo Limited, H1 2024 Earnings Call, Feb 27, 2024 |
| Sales 2024 * | 103M 65.94M | Sales 2025 * | 133M 85.62M | Capitalization | 1.42B 913M |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 1.93M | Net income 2025 * | 13M 8.35M | EV / Sales 2024 * | 13.4 x |
| Net cash position 2024 * | 42.64M 27.38M | Net cash position 2025 * | 37.06M 23.8M | EV / Sales 2025 * | 10.4 x |
| P/E ratio 2024 * |
342
x | P/E ratio 2025 * |
105
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyNovo Limited
More news
| 1 day | +0.98% | ||
| 1 week | -4.63% | ||
| Current month | -5.94% | ||
| 1 month | -12.34% | ||
| 3 months | +33.77% | ||
| 6 months | +70.95% | ||
| Current year | +24.47% |
1 week
2.00
2.16
1 month
2.002.29
Current year
1.482.52
1 year
1.102.52
3 years
0.843.19
5 years
0.844.08
10 years
0.074.08
| Managers | Title | Age | Since |
|---|---|---|---|
Swami Raote
CEO | Chief Executive Officer | - | 22-07-28 |
| Director of Finance/CFO | - | 18-12-11 | |
Philip Scorgie
CTO | Chief Tech/Sci/R&D Officer | - | 23-05-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 14-02-27 | |
Bruce Rathie
BRD | Director/Board Member | 68 | 10-02-17 |
| Chief Tech/Sci/R&D Officer | - | 12-08-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 7 M€ | -0.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.965 | -4.61% | 1 232 169 |
| 24-04-18 | 2.06 | +0.98% | 801,832 |
| 24-04-17 | 2.04 | +1.49% | 836,390 |
| 24-04-16 | 2.01 | -6.51% | 1,354,761 |
| 24-04-15 | 2.15 | 0.00% | 1,208,939 |
Delayed Quote Australian S.E., April 18, 2024 at 02:10 am EDT
More quotes
PolyNovo Limited is an Australia-based company, which is engaged in the development of medical devices for various medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM product is designed to help surgeons treat traumatic wounds. NovoSorb BTM may be used to temporarily close the wound and aid the body in generating new tissue. It is indicated for full or deep partial-thickness burns, surgical and reconstructive wounds and traumatic wounds. BTM is applied to a wound once the unhealthy or dead tissue has been surgically removed. NovoSorb is a medical-grade polymers that can be expressed in a range of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products.
Calendar
2024-08-21
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.06
AUD
Average target price
2.113
AUD
Spread / Average Target
+2.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.47% | 904M | |
| -4.36% | 184B | |
| -3.87% | 105B | |
| -4.38% | 67.09B | |
| +8.23% | 51.61B | |
| +15.54% | 47.55B | |
| +0.60% | 39.95B | |
| +7.16% | 27.62B | |
| -12.48% | 25.74B | |
| -1.68% | 25.62B |
- Stock Market
- Equities
- PNV Stock
